文献速递肝胆胰外科围术期管理与 ERAS

动脉周围剥离治疗交界可切除及局部晚期胰腺癌:单中心125例分析

Periarterial divestment for borderline and locally advanced pancreatic cancer: An analysis of 125 cases in a single center.
PubMed 文献 · Surgery · 2025-05-20

该单中心回顾性研究分析125例行动脉周围剥离的交界可切除或局部晚期胰腺导管腺癌患者,评估Neuro-Patch动脉加固预防胰切除后出血的疗效及肿瘤学结局。结果显示Neuro-Patch显著降低胰切除后出血风险,新辅助化疗和静脉侵犯是总生存的独立预测因素。

要点

  • Neuro-Patch动脉加固可显著降低胰切除后出血风险(OR 0.073)。
  • 新辅助化疗是总生存的独立保护因素(HR 0.494)。
  • 静脉侵犯是总生存的独立危险因素(HR 2.041)。

核心结论

  • 新辅助化疗显著改善行动脉周围剥离的交界可切除或局部晚期胰腺导管腺癌患者生存,应视为标准术前策略。
  • Neuro-Patch为动脉壁提供结构加固,可能降低胰切除后出血风险,但需随机对照试验证实其疗效与安全性。

研究设计与样本

  • 单中心回顾性分析2018年1月至2022年5月间125例涉及动脉的交界可切除或局部晚期胰腺导管腺癌行动脉周围剥离的患者。

主要发现

  • 54例行胰十二指肠切除术,43例行远端胰腺切除术,28例行全胰腺切除术,74例同时行联合静脉切除。
  • 动脉周围剥离涉及肝动脉47例、腹腔干3例、肠系膜上动脉22例、多动脉53例。
  • 24%患者接受新辅助化疗,R0切除率33.6%,术后中位住院10天,90天死亡率3.2%。

临床怎么用

  • 对交界可切除或局部晚期胰腺导管腺癌行动脉周围剥离患者,应考虑新辅助化疗作为标准术前治疗。
  • 术中可考虑使用Neuro-Patch对动脉壁进行结构加固以降低胰切除后出血风险,但需待随机对照试验进一步验证。

局限性

  • 本研究为单中心回顾性分析,样本量有限,结论需随机对照试验证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Literature on factors influencing prognosis after periarterial divestment for borderline resectable or locally advanced pancreatic ductal adenocarcinoma and preventative measures for postpancreatectomy hemorrhage is scarce. This study aimed to evaluate the efficacy of Neuro-Patch for arterial reinforcement in preventing postpancreatectomy hemorrhage and explore the oncologic outcomes of patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma following periarterial divestment. METHODS: We conducted a retrospective analysis of 125 patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma involving arteries who underwent periarterial divestment between January 2018 and May 2022. RESULTS: Among the study cohort, 54 patients underwent pancreaticoduodenectomy, 43 had distal pancreatectomy, and 28 received total pancreatectomy, with 74 patients also undergoing combined venous resection. Periarterial divestment was performed on the hepatic artery in 47 patients, the celiac artery in 3, the superior mesenteric artery in 22, and multiple arteries in 53. Neoadjuvant chemotherapy was administered to 24% of patients, with an R0 resection rate of 33.6%. The median postoperative hospital stay was 10 days, with a 90-day mortality rate of 3.2%. Neuro-Patch was used in 51 patients, leading to a significant reduction in postpancreatectomy hemorrhage (odds ratio 0.073, 95% confidence interval 0.007-0.783, P = .031). The median overall survival was 20.6 months, with 1- and 3-year survival rates estimated at 73.2% and 22.9%, respectively. Neoadjuvant chemotherapy (hazard ratio 0.494, 95% confidence interval 0.291-0.839, P = .009) and venous invasion (hazard ratio 2.041, 95% confidence interval 1.308-3.186, P = .002) emerged as independent predictors of overall survival. CONCLUSION: Neoadjuvant chemotherapy significantly enhances survival outcomes of patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma undergoing periarterial divestment, and it should be regarded as a standard preoperative approach. The Neuro-Patch provides structural reinforcement to the arterial wall, potentially reducing the risk of postpancreatectomy hemorrhage. However, randomized controlled trials are necessary to substantiate its efficacy and safety.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Yang F, Xu Y, Jin C, et al. Periarterial divestment for borderline and locally advanced pancreatic cancer: An analysis of 125 cases in a single center. Surgery. 2025. PMID: 40398370. doi:10.1016/j.surg.2025.109412

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。